| Literature DB >> 31401124 |
Andrea Gaedigk1, Amy Turner2, Robin E Everts3, Stuart A Scott4, Praful Aggarwal2, Ulrich Broeckel2, Gwendolyn A McMillin5, Roberta Melis6, Erin C Boone1, Victoria M Pratt7, Lisa V Kalman8.
Abstract
Pharmacogenetic testing increasingly is available from clinical and research laboratories. However, only a limited number of quality control and other reference materials currently are available for the complex rearrangements and rare variants that occur in the CYP2D6 gene. To address this need, the Division of Laboratory Systems, CDC-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing and research communities and the Coriell Cell Repositories (Camden, NJ), has characterized 179 DNA samples derived from Coriell cell lines. Testing included the recharacterization of 137 genomic DNAs that were genotyped in previous Genetic Testing Reference Material Coordination Program studies and 42 additional samples that had not been characterized previously. DNA samples were distributed to volunteer testing laboratories for genotyping using a variety of commercially available and laboratory-developed tests. These publicly available samples will support the quality-assurance and quality-control programs of clinical laboratories performing CYP2D6 testing.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31401124 PMCID: PMC6854474 DOI: 10.1016/j.jmoldx.2019.06.007
Source DB: PubMed Journal: J Mol Diagn ISSN: 1525-1578 Impact factor: 5.568